STOCK TITAN

Attovia Therapeutics (ATTO) director lists indirect Series B and C preferred stakes

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. director Colin Walsh reported initial indirect holdings of the company’s preferred stock. The filing lists Series B Preferred Stock convertible into 1,957,140 shares of common stock and Series C Preferred Stock convertible into 478,501 shares of common stock, all held through Goldman Sachs–affiliated investment vehicles. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider WALSH COLIN
Role Director
Type Security Shares Price Value
holding Series B Preferred Stock F1, F2, F3 -- -- --
holding Series C Preferred Stock F1, F2, F3 -- -- --
Holdings After Transaction: Series B Preferred Stock — 1,957,140 shares (Indirect, See Footnote); Series C Preferred Stock — 478,501 shares (Indirect, See Footnote)
Footnotes (3)
  1. F1. The Reporting Person is a managing director of Goldman Sachs & Co LLC ("GS&Co"), a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co. and an indirect owner of Goldman Sachs Asset Management, L.P. ("GSAM LP"). GS&Co. is the manager of Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock of the Issuer. GSAM LP is the investment manager of WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly owns 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock of the Issuer,... [continued in footnote 2]
  2. F2. [continued from footnote 1]... West Street Life Sciences I, L.P. ("WSLS I"), which owns 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock of the Issuer, WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which owns 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock of the Issuer, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock of the Issuer.
  3. F3. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Underlying common shares from Series B Preferred Stock 1,957,140 shares Indirect holdings reported by Colin Walsh, underlying security shares
Underlying common shares from Series C Preferred Stock 478,501 shares Indirect holdings reported by Colin Walsh, underlying security shares
Exercise/conversion price 0.0000 Conversion or exercise price for both Series B and Series C Preferred Stock
Series B Preferred Stock financial
"Series B Preferred Stock convertible into 1,957,140 shares of common stock"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Series C Preferred Stock financial
"Series C Preferred Stock convertible into 478,501 shares of common stock"
A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.
beneficial ownership financial
"disclaims beneficial ownership of the securities reported herein except to the extent"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of the Reporting Person's pecuniary interest therein, if any"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Colin Walsh report owning in Attovia Therapeutics (ATTO) on this Form 3?

Colin Walsh reported indirect holdings of Series B and Series C Preferred Stock of Attovia Therapeutics, convertible into 1,957,140 and 478,501 common shares, respectively, through Goldman Sachs–affiliated investment entities.

Are Colin Walsh’s Attovia (ATTO) holdings direct or indirect?

The Form 3 shows Walsh’s Attovia interests as indirect holdings. The Series B and Series C Preferred Stock positions are held through Goldman Sachs–affiliated investment vehicles rather than in his personal name.

How many Attovia (ATTO) common shares are underlying Colin Walsh’s Series B Preferred Stock?

The Series B Preferred Stock position reported for Colin Walsh is convertible into 1,957,140 shares of Attovia common stock, according to the underlying security share count disclosed in the Form 3.

How many Attovia (ATTO) common shares are underlying Colin Walsh’s Series C Preferred Stock?

The Series C Preferred Stock position reported is convertible into 478,501 shares of Attovia common stock. This figure reflects the underlying common shares associated with the indirect preferred stock holdings.

Does Colin Walsh disclaim beneficial ownership of his reported Attovia (ATTO) securities?

Yes. A footnote states Walsh disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest, and clarifies that the filing should not be deemed an admission of beneficial ownership.

Which entities are associated with Colin Walsh’s Attovia (ATTO) preferred stock holdings?

Footnotes explain that the reported Series B and Series C Preferred Stock are held by Goldman Sachs–affiliated entities, including Goldman Sachs & Co. LLC and various Broad Street and West Street Life Sciences investment vehicles.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
WALSH COLIN

(Last)(First)(Middle)
C/O GOLDMAN SACHS GROUP INC.
2OO WEST STREET

(Street)
NEW YORK NEW YORK 10282

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026
3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Series B Preferred Stock (1)(2)(3) (1)(2)(3)Common Stock1,957,140$0ISee Footnote(1)(2)(3)
Series C Preferred Stock (1)(2)(3) (1)(2)(3)Common Stock478,501$0ISee Footnote(1)(2)(3)
Explanation of Responses:
1. The Reporting Person is a managing director of Goldman Sachs & Co LLC ("GS&Co"), a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co. and an indirect owner of Goldman Sachs Asset Management, L.P. ("GSAM LP"). GS&Co. is the manager of Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock of the Issuer. GSAM LP is the investment manager of WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly owns 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock of the Issuer,... [continued in footnote 2]
2. [continued from footnote 1]... West Street Life Sciences I, L.P. ("WSLS I"), which owns 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock of the Issuer, WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which owns 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock of the Issuer, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock of the Issuer.
3. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Remarks:
/s/ Crystal Orgill, Attorney-in-fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)